Opinion

Video

Clinical Insights: Exploring Combination Regimens in First-Line Treatment in CLL: SEQUOIA Arm D and BOVen Trials

Panelists discuss how the combination of zanubrutinib plus venetoclax in arm D of the SEQUOIA trial contributes to understanding the potential role of BTK inhibitor and BCL2 inhibitor combinations in frontline CLL treatment.

Video Player is loading.
Current Time 0:00
Duration 4:16
Loaded: 3.83%
Stream Type LIVE
Remaining Time 4:16
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
  • en (Main), selected

Video content above is prompted by the following:

  • There are many ongoing frontline combination studies in CLL, and what are your impressions of the arm D – zanu plus venetoclax data in the SEQUOIA trial?